anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A number of studies have documented an average of 47% greater weight gain in preterm neonates following massage therapy. Our currently funded study suggests that massage therapy increases vagal activity, oxytocin, and IGF-1. In the proposed continuation of this study preemies would be provided daily massages three times a day for 10 days, as in our previously successful protocol. To determine potential mechanisms that may underlie the massage therapy/weight gain relationship we will continue to assess vagal activity and assay insulin, oxytocin, IGF-1 and cortisol as well as gastric motility. We have added an alternative potential pathway for the massage therapy/weight gain relationship. In this expanded model, activity level and the related measures of heart rate, oxygen consumption (based on a formula calculated from heart rate) and temperature mediate the effects of massage therapy on weight gain. A larger sample will be recruited so that we can have the power needed to test our model of the potential mechanisms underlying the weight gain from preterm infant massage. For the current application, 120 preterm infants with common medical complications of prematurity, who are medically stable and residing in the intermediate care ("grower") nursery, will be assigned to groups based on a random stratification on the following variables: gender, gestational age, birthweight, days in the NICU, and study entry weight. One hundred twenty infants will be randomly assigned to one of two groups: 1) ten days of massage therapy (n=60), or 2) standard treatment (n=60). Within-subjects and between-groups analyses will focus on physiological (heart rate, vagal tone, gastric motility, and temperature), biochemical (insulin, oxytocin, IGF-1 and cortisol) and behavioral variables (activity level).
The endoscopic procedure was done under general anesthesia, and all patients received antibiotic prophylaxis. We used the subureteral injection technique (STING), as described by O'Donnell and Puri (1984). The volume of Dx/HA was injected until ureteral orifice collapse in all patients. The needle was held for 30 s.
FIELD: medicine. SUBSTANCE: method involves incubating whole patient blood treated with heparin in the amount of 10% of the total circulating blood volume in the presence of 0.5-1 mln of MU of recombinant alpha-interferon at 37 C during 90-180 min. Then, the blood is returned to the vascular bed of the same patient. The procedure is carried out 1-2 times a week during 1-1.5 months. EFFECT: enhanced effectiveness of treatment; normalized alanine aminotransferase, aspartate aminotransferase, hypoxanthine-guanine transferase, alkaline phosphatase indices. 1 tbl
The utilisation of mink fat (I), either unhomogeneous or pretreated, for pharmaceutical or cosmetic purposes, is improved when (I) is heated, pref. at about 100 degrees C, with a sulphur iodide (II), so as to give a homogeneous oil free from solids and suspended matter. (II) may be replaced at least in part by S or mixts. of (II) and S are used. (I) is used in hair- and skin-care compsn. because of its excellent wetting ability (surface tension is only 31 dynes/cm2). Treatment with (II) greatly improves stability and gives a prod. which is rapidly and completely taken up by the skin or hair without irritation.
Post-transplant lymphoproliferative disease (PTLD) is a rare but serious complication of liver transplantation (LT) with morbidity and mortality. The risk factors for PTLD in adults are ill-defined. This study aimed to assess the risk factors for PTLD after LT in adults. All adult LT recipients between 1986 and 2016 from 2 centers in the Netherlands were included, with follow-up until 2020. PTLD was diagnosed according to the World Health Organization (WHO) classification. Potential risk factors for PTLD were assessed using multivariate Cox regression analysis. A total of 1281 patients were included, of whom 29 (2.3%) developed PTLD. Results show that independent risk factors for PTLD after LT in adults were no Epstein-Barr virus load monitoring strategy, primary sclerosing cholangitis as an indication for LT, era (historic era linked to more intense long-term immunosuppression), and Epstein-Barr virus-seronegative recipient. No other independent risk factors were identified in this study. Of the 207 patients with primary sclerosing cholangitis as an indication for LT, 13 (6.3%) developed PTLD versus 16 out of 1074 (1.5%) patients with other underlying liver diseases (log-rank p <0.001). The yearly PTLD incidence was higher in the first year than in the later years after LT (2.4%/y vs. 0.6%/y) for primary sclerosing cholangitis, but not for other indications (0.16%/y). In Epstein-Barr virus-seronegative recipients PTLD occurred earlier after LT, while in 97% of seropositive recipients it could occur very late after LT.
Diabetic nephropathy (DN) is a severe complication of prolonged diabetes, impacting millions worldwide with an increasing incidence. This study investigates the role of tribbles pseudokinase 3 (TRIB3), a protein implicated in the progression of DN, focusing on its mechanisms underlying glomerular damage. Through analysis of the Gene Expression Omnibus (GEO) database, we identified TRIB, among differentially expressed genes (DEGs) in streptozotocin (STZ)-treated C57BL/6J mice. Both in vitro and in vivo experiments were conducted to examine the effects of TRIB3 inhibition on high glucose (HG)-induced damage in podocytes and DN mouse models. The results demonstrated that TRIB3 inhibition reduced inflammatory responses and extracellular matrix (ECM) production inMPC5 cells, mediated by the downregulation of DNA damage-inducible transcript 3 (DDIT3) - a critical regulator of proinflammatory cytokine secretion and ECM synthesis. Inhibiting TRIB3 decreased inflammatory factors and ECM deposition in diabetic mice in vivo, confirming its pivotal role in DN pathogenesis. These findings indicate that TRIB3 and its interaction with DDIT3 contribute significantly to DN by promoting inflammatory cascades and ECM accumulation, presenting potential therapeutic targets for managing the disease.
OBJECTIVES: This retrospective study aimed to investigate the effectiveness and safety of early combined therapy with CT-guided paravertebral nerve (PVN), pulsed radiofrequency (PRF), and subcutaneous block on acute/subacute herpes zoster (HZ).
METHODS: A total of 98 medical records were analyzed. All patients underwent CT-guided PRF on PVN immediately followed by a single subcutaneous block with lidocaine and dexamethasone in acute/subacute phase. The therapy efficacy was evaluated by pain numeric rating scale (NRS) and effective rate, which was defined as a percent of cases with a reduction in pain NRS>50% at day 1, week 2, 4, 12, and 24 after the procedure. The incidences of medication reduction and postherpetic neuralgia (PHN) were also retrieved. Further comparison was conducted between acute group (disease duration<30 days from HZ onset) and subacute group (30 day<duration<90 days from HZ onset).
RESULTS: Early combined therapy indicated an immediate and sustained improvement in pain NRS as compared with before treatment ( P <0.0001), with effective rates of 74%, 79%, 80%, 76%, and 79% at day 1, week 2, 4, 12, and 24 after procedure, respectively. At the end of follow-up, the proportion of patients with a reduction of >50% in prior medications amounted to 83% and the incidence of clinically meaningful PHN decreased to 23%. The clinical efficacy was more profound in acute group than in subacute group at every time points ( P <0.05). No severe complications occurred.
DISCUSSION: Our data revealed surprising levels of pain relief by combination therapies of PRF and subcutaneous block targeting different sites of pain pathway, thus suggesting a valuable treatment option for acute/subacute herpetic neuralgia.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to novel fenofibrate medicinal form of immediate release for oral administration that comprises water-soluble inert base covered by at least one cover layer. Cover comprises fenofibrate in micronized form with particles size less 20 mcm, hydrophilic polymer and, if necessary, surface-active substance. Hydrophilic polymer comprises at least 20% of inert base weight with cover and it is polyvinylpyrrolidone. Method of preparing the novel fenofibrate medicinal form involves preparing fenofibrate suspension in micronized form with indicated particles size in hydrophilic polymer solution and, if necessary, surface-active substance and its application on water-soluble inert base. New medicinal form exhibits the higher fenofibrate dissolving approximating to 100%, i. e. the higher biological potential that provides decrease of daily dose of drug and requires a single intake per a day. EFFECT: improved and valuable properties of medicinal form. 20 cl, 2 dwg, 1 tbl, 4 ex
A skin enhancing composition is provided. The skin enhancing composition comprises filtered water, at least two antioxidants, one or more plant components, an anti-inflammatory agent, and an alpha hydroxy acid. The antioxidants neutralize endogenous free radicals, thereby reducing cell damage and the visual effects of aging. The antioxidants comprise cannabinoid distillates, l-glutathione, d-alpha tocopherol, trans-resveratrol, or citric acid. The plant components are derived from any whole or partial fruit, vegetable or other plant, or an extract thereof. The anti-inflammatory agent, such as ascorbic acid, supports white blood cells and improves the health and appearance of skin by evening out skin tone, shielding the skin from visible impacts of pollution, and improving hydration. The alpha hydroxy acids improve skin evenness and tone and reduce wrinkles and other signs of aging. In some embodiments, additional vitamins, minerals, one or more natural flavors, and one or more natural colors are also provided.
Anesthesia is a controlled, temporary loss of sensation or awareness used to perform surgical procedures. Spinal anesthesia is commonly used in obstetrics and gynecology for vaginal procedures as well as cesarean sections. The use of spinal anesthesia for laparoscopic surgery is an adequate and safe alternative to general anesthesia which remains the gold standard. Vaginal Natural Orifice Endoscopic Surgery (vNOTES) is a minimally invasive laparoscopic approach used for tubal sterilization that is currently performed under general anesthesia. This study is proposing that spinal anesthesia is an adequate and safe alternative to general anesthesia for vNOTES tubal sterilization. If participants join the study, all other routine care will continue but the researchers will randomly assign participants, like flipping a coin, to one of two groups. Both types of anesthesia are commonly used but the researchers are doing this study because it is not known if spinal anesthesia is a better alternative than general anesthesia which is typically used. The goal is to find out what might be best for future patients. If it turns out the two types of anesthesia are about the same, then surgeons would know that choosing the type with fewer side effects still gives satisfactory results and allows for this surgery to be performed safely. The risks involved in participating in this study are the same as all other anesthetic and surgical procedures which have significant physical risks. If participants choose to enroll, there will be a 50/50 chance of being assigned to either the standard of care group which will receive general anesthesia or the experimental group which will receive spinal anesthesia. Benefits cannot be guaranteed but, It is possible participants could be assigned to a type of anesthesia that has fewer side effects.
Standard physiotherapy includes routine physiotherapy care as per current institutional standards. This consists of two daily visits by the physiotherapist. During the visits, the patient will be taught deep breathing and will be instructed to practice it 10 times every hour. They are also shown shoulder movements and lung expansion exercises. They will receive a sheet summarizing the exercises for future reference. The patient is discharged from physiotherapy when they are ambulatory, on room air, and able to clear their respiratory secretions independently, although they will be asked to continue the exercises on their own until 30 days from surgery.
Obese non-diabetic: HbA1c\<5.7%, No signs and history of T2D, and BMI\>30 kg/m2 (n=30). Blood sample analysis (Blood samples will be taken for the analysis of GLP-1, Peptide YY, glucose and insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test).
A method for prevention or treatment of a viral-mediated infectious disease in a mammal. The mammal may be a human being. A therapeutic dose of a composition is administered, via an inhalation delivery apparatus, to the mammal. The composition includes microparticles and/or nanoparticles. The microparticles and/or nanoparticles include a first pharmaceutically active agent and a second pharmaceutically active agent. The first pharmaceutically active agent includes unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH) or combinations thereof. The second pharmaceutically active agent includes 10-30 mg of hydroxychloroquine in a form of hydroxychloroquine sulfate, 10-30 mg of favipiravir, or a combination thereof. The viral-mediated infectious disease is caused by one or more viruses in the mammal.
PURPOSE:To obtain hair-treating agent having excellent property to form and keep the style of the hair, by using keratin decomposition derivative and glucoside and/or polyphenol compound as essential components. CONSTITUTION:The objective hair-treating agent contains (A) 0.05-10.0wt% keratin decomposition derivative selected from hydrolyzed keratin, alkali metal salt of the oxidative decomposition product of keratin, and alkali metal salt of a derivative of reduction decomposition product of keratin at the thiol group, or their mixture and (B) 0.001-5.0wt% glucoside and/or a polyphenol compound. The keratin of the component (A) is preferably wool, hair, or feather. The glucoside and the polyphenol compound of the component (B) are preferably saponin and a tannin derivative, respectively. Both components are dissolved in a proper solvent, or converted to an emulsion, gel, etc. to obtain the objective treating agent.
Temporomandibular/orofacial pain disorders (TMD) are a group of painful conditions with multiple determinants. A number of psychosocial treatments for TMD have been developed, but overall effectiveness has been limited, and the mechanisms of treatment are unknown. This proposal has two main goals: 1) to test a highly individualized, adaptive treatment for TMD that has potential to be more effective than other psychosocial treatments; and 2) to discover the mechanisms by which psychosocial treatments work in chronic pain. Patients with TMD-related pain of at least 3 months duration (N=160) will be randomly assigned to either a Standard Conservative Treatment +Cognitive Behavioral coping skills treatment (STD+CBT), or to an Individualized Assessment and cognitive-behavioral Treatment Program (IATP) for patients with TMD pain. Treatment in IATP will be based on a very detailed functional analysis of the patient's pain experience, in context, as derived from Experience Sampling (ES). The ES procedure will be conducted via smartphone app at a rate of 4 records per day, and will be used to gather information on patients' pain, momentary cognitions, affects, and coping behaviors, for a 2-week monitoring period prior to the beginning of treatment. Therapists will use this information to develop an individual functional analysis of pain and non-pain episodes, and determine what thoughts, feelings and actions are effective for that patient at managing pain and which are not. The information will be used to help develop adaptive coping tactics in a 6-session treatment program, offering skills training tailored to specific patient needs. During-treatment ES will allow adjustment of the treatment goals and procedures, making the treatment adaptive and able to change with changing circumstances and patient needs. This experimental treatment (IATP) will be added to a standard conservative splint-based treatment for TMD pain (STD). The combination (STD+IATP) will be compared to a STD treatment supplemented with a 6 session conventional cognitive-behavioral program not based on in-vivo assessment of pain and coping. In the STD+CBT condition ES data will be collected but will not be used to inform treatment, but will control for measurement reactivity. ES data collected prior to, during, and following both treatments (out to 12 months) will allow very precise measurement of cognitions, affects, and coping skills, as they occur in patients' home environments, and how they change over time. Outcomes will include measures of pain, interference, and depressive symptoms. It is expected that the STD+IATP treatment will yield lower pain, depression and interference scores over time than STD+CBT, and that changes in coping ability will mediate the treatment effects on outcomes. The study will be able to tailor treatment based on patient experiences measured in near-real time at pain episodes, allow for adaptation of treatment as it progresses, and measure the impact on outcomes of coping changes over the long-term. The results will shed light on active mechanisms of treatment for TMD and may have implications for the management of other chronic pain conditions.
NEW MATERIAL:The phthalazone derivative of formula I (R is H or lower alkyl; A is group of formula II or formula III; n is 0-14). EXAMPLE:7-Ethoxycarbonyl-6,8-dimethyl-1( 2H )-phthalazinon-4-ylmethyl hydrogen succinate. USE:Useful as a biotransformation precursor of phthalazinol which is useful as a preventive and remedy for hypertensive, arteriosclerotic and thrombotic diseases. The compound is converted to phthalazinol in the body to exhibit the pharmacological activity, and is useful as a remedy for angiopathy. PROCESS:Phthalazinol of formula IV is esterified with a carboxylic acid or its functional derivative, and the 4-hydroxymethyl group is converted to CH2-A-OR group to obtain the compound of formula I . The carboxylic acid or its functional derivative is, e.g. oxalic acid, adipic acid monoethyl ester, etc.
Systems and methods for expediting medical image retrieval based on examination priority are provided. A method includes receiving medical images and parsing the contents to determine medical image information. The method includes applying priority rules based on the medical image information. The priority rules specify an image storage location for storing the medical images. The image storage locations include workstation cache memory and drives of a local storage system having different image access speeds that are slower than an access speed of the workstation cache memory. The method includes storing the medical images at the specified image storage location as defined by the priority rules and retrieving the medical images from the specified image storage location in response to a request to view the medical images at a workstation. The method includes presenting the medical images retrieved from the specified image storage location at a display device of the workstation.
Thoracic cancers comprise non-small cell lung cancers (NSCLCs), small cell lung cancers (SCLCs) and malignant pleural mesotheliomas (MPM). Collectively, they account for the highest rate of death from malignancy worldwide. Genomic instability is a universal feature of cancer, which fuels mutations and tumour evolution. Deficiencies in DNA damage response (DDR) genes amplify genomic instability. Homologous recombination deficiency (HRD), resulting from BRCA1/BRCA2 inactivation, is exploited for therapeutic synthetic lethality with poly-ADP ribose polymerase (PARP) inhibitors in breast and ovarian cancers, as well as in prostate and pancreatic cancers. However, DDR deficiency and its therapeutic implications are less well established in thoracic cancers. Emerging evidence suggests that a subset of thoracic cancers may harbour DDR deficiency and may, thus, be effectively targeted with DDR agents. Here, we review the current evidence surrounding DDR in thoracic cancers and discuss the challenges and promise for achieving clinical benefit with such therapeutics.
Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H1-histaminergic, or α1-adrenergic receptors in vitro. Desvenlafaxine also lacked monoamine oxidase (MAO) inhibitory activity. 

ECG changes

Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks. No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals. In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation. No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.
In this study, we will determine whether patients with MACS (versus healthy age and sex matched controls) demonstrate: 1) decreased bone strength and quality disproportionate to the decrease of bone density and 2) abnormalities in the steroid metabolome correlate with the degree of abnormalities in bone parameters. In a cross-sectional study of 75 patients with MACS and 75 age- and sex-matched healthy controls, we will determine the relationship of the steroid metabolome to measurements of bone density, quality and strength, bone turnover markers, as well as body composition. All patients will be interviewed in regards to their health, to include questions on bone health, frailty, cognition (NIH toolbox), and quality of life. We will measure 1) BMD (bone mineral density) at the lumbar spine, hip and radius and body composition using dual-energy X ray absorptiometry (DXA), 2) radial and tibial bone microstructure by high-resolution peripheral quantitative computed tomography (HR-pQCT), 4) bone turnover markers (osteocalcin, PINP, CTx, sclerostin). 5) Age reader measurement, 6) hand grip measurement, 7) 6 minute walk test. All patients will provide a 24 h urine for steroid metabolome analysis. For primary outcomes, we will determine if steroid metabolome profiling better predicts abnormal bone strength (as measured by trabecular bone volume/tissue volume \[BV/TV\] ratio).
PURPOSE:To obtain an antitumor agent useful for treating malignant tumor, having antitumor activity, immune enhancing activity, safety in terms of toxicity to human body and side effects, rapidly showing medicinal effects, containing a polysaccharide comprising galactosamine as an active ingredient. CONSTITUTION:An antitumor agent having a polysaccharide comprising galactosamine (e.g. galactosamine polymer produced by Aspergillus parasticus) as an active ingredient. The antitumor agent shows excellent antitumor activity even with a small amount of does and a few times of administration. The antitumor agent is effective against tumor cell of sarcoma 180, Ehrlich carcinoma, etc. A dose is 0.1mug/kg-100mg/kg, preferably 0.1mug/kg-100mug/kg daily per adult.